comprehensive -WSS

comprehensive

author：entertainment 2025-09-27 23:02:18 - browse：9995

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： ER docs worry over extreme heat as a 'mass casualty event'

WSS

Investigation reveals sickle cell patients pressured into sterilizations

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Listen: A conversation with researcher Kevin Esvelt on biosecurity

15 die by electrocution after transformer explodes in northern India

House passes resolution saying Israel isn't a 'racist or apartheid state'

Listen: More tumult at BIO & coercive care for sickle cell patients

knowledge

comprehensive

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

DIEP, the 'gold standard' of breast reconstruction, is under threat

Digital health: a case of mistaken identity

Walensky prepares to leave CDC — and Congress — behind

Making the case for fair compensation in clinical trials

BioMarin wins approval for gene therapy to treat hemophilia A

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

How one medical school became remarkably diverse

Liver decline slowed by off

focus

A strong 6.5

What we know about the American soldier detained in North Korea

Lack of darker skin in textbooks, journals harms patients of color

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Fentanyl is making it harder to start addiction treatment

Biogen joins immunology wave with $1.15 billion acquisition of HI

hotspot

focus

focus

focus